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The DNA genomes of four new human papillomaviruses, HPV 75, HPV 76, HPV 77, and HPV 80, have been cloned,
sequenced, and characterized. HPV 75, HPV 76 (both HPV 49-related), and HPV 77 (HPV 29-related) were isolated from
benign cutaneous warts and HPV 80 (HPV 15-related) from histologically normal skin. HPV 77 has also been demonstrated
in dysplastic warts and squamous cell carcinomas of the skin. The sequence data presented in this study led to a proposed
modification of the definition of a new HPV type. The high degree of DNA sequence similarity between the E7 ORF of HPV
77 and HPV 29 (97.7%), as opposed to the E6 (82.8%) and L1 (85.3%) ORFs, might suggest conservation of a specific function
or a possible recombinational event. Only the E6 and L1 ORFs of HPV 75 and HPV 76 have a similarity lower than 90%,
whereas the DNA sequences of their upstream regulatory regions (URRs) share a similarity of 93%. The E7, E1, and E4 ORFs,
as well as the URR of HPV 15 and HPV 80, share sequence similarities higher than 90%. Such a divergence in the similarity
between different segments of the virus genomes of closely related HPV types has not been noted to date. A detailed
comparative sequence analysis was performed. HPV 75, HPV 76, and HPV 80 revealed features characteristic of truly
cutaneous HPV types, whereas HPV 77 shared several characteristics with the mucosal HPV types, some of which may have
functional consequences.
INTRODUCTION
The DNA sequences of the double-stranded genomes of
the majority of HPV types have become available during
recent years (Delius and Hofmann, 1994, and Delius, un-
published results). This allowed more exact analyses of
and comparisons between the DNA genomes of different
papillomavirus types. The genome of a papillomavirus is
constituted of distinct open reading frames (ORF). Each
ORF features characteristic patterns which have been con-
served between types despite the general heterogeneity
within this virus group. A DNA sequence similarity of less
than 90% between all three ORFs, E6, E7, and L1, of the
putative new type to that of the closest related known type
defined the full-length genome as a new papillomavirus
type (de Villiers, 1994). The L1 ORF coding for the outer
capsid protein is highly conserved among types, whereas
the E6 and E7 ORFs, coding for the transforming genes in
the high-risk genital HPV types, are generally less con-
served and were included due to their functional impor-
tance. The first 74 HPV types were defined in this manner.
The isolation and characterization of four new types, HPV
75, HPV 76, HPV 77, and HPV 80, described in this study,
provided information which led to a reevaluation of the
definition of a papillomavirus type (14th International Papil-
lomavirus Conference, Quebec, 1995). The similarities be-
tween the early open reading frames of the closest related
types exceed the 90% limit, whereas that of the L1 ORF
does not. The L1 ORF codes for the major structural protein
with type-specific antigenicity and it was therefore pro-
posed to define a new type based on a similarity of less
than 90% in the L1 ORF only. Comparative analyses per-
formed between the sequences of the HPV types described
here may hint of but do not resolve the question of whether
recombinational events did occur between different HPV
types during the course of evolution. Certain sequence
motifs present in the HPV 77 sequence group this HPV type
with the genital HPV types, although it was isolated from,
and subsequently detected in, cutaneous lesions. HPV 75,
HPV 76, and HPV 80, in contrast, display typical cutaneous
type characteristics.
RESULTS
The amplification by polymerase chain reaction of cel-
lular DNA from tumor biopsies with subsequent cloning
and sequencing of the products led to the identification
of yet unidentified HPV sequences (Shamanin et al.,
1994b). The partial DNA sequence of the L1 ORF was in
each case used as a probe to identify clones from the
DNA libraries of the respective tumors which harbored
the full-length (ca. 8-kb) genome. The genomes VS40-7-G
(HPV 75) and CR148-G (HPV 76) and the 4-kb fragment of
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VS93-1-G (HPV 77) were cloned into the respective plas-
mids, whereas all similar attempts with the 3.5-kb BamHI
fragment of VS93-1-G (HPV 77) and KB-G (HPV 80) failed.
Attempts to propagate these DNAs in a variety of plas-
mids failed, possibly due to toxic sequences. This forced
us to maintain these isolates in Lambda Zap Express
and l1149, respectively.
The full-length nucleotide sequences of the four ge-
nomes were established using these lambda and plas-
mid clones. HPV 75 consists of 7537 nucleotides, HPV 76
of 7549 nucleotides, HPV 77 of 7887 nucleotides, and
HPV 80 of 7427 nucleotides. The sequences of the ge-
nomes revealed all the major ORFs characteristic for
papillomaviruses. The positions of these ORFs and the
number of amino acids of their putative encoded proteins
are summarized in Table 1. The DNA sequences of the
E6, E7, and L1 ORFs were aligned to the corresponding
ORF of the respective closest related known HPV type in
order to determine whether these genomes constituted
new HPV types (Table 2). The percentage similarities
among the E6, E7, and L1 ORFs of HPV29/HPV 77 were
82.8, 97.7, and 85.3%, respectively, those between HPV
75/HPV 76 were 89.8, 93.7, and 88.2%, between HPV
76/HPV49 78.0, 83.1, and 79.2%, between HPV 75/HPV 49
77.5, 83.4, and 79.6%, and between HPV 15/HPV 80 87.2,
93.5, and 86.8%.
The 2.3% difference between the E7 ORFs of HPV 77
and HPV 29 was detectable in single scattered nucleo-
tides. The similarity of the E7 ORFs between HPV 15 and
HPV 80 is 93.5% and between HPV 75 and HPV 76 93.7%,
which are both above the 90% similarity limit of the
present definition. The high degree of similarity between
the E7 ORFs of HPV 77 and HPV 29 (97.7%), as opposed
to the E6 (82.8%) and L1 (85.3%) ORFs, might suggest
conservation of a specific function or a possible recom-
binational event. A closer look at the neighboring 300
nucleotides of the neighboring E1 ORF (E1P, Table 3)
shows a lower degree of similarity (89.7%) and no indi-
cation of an uneven distribution of deviating nucleotides,
arguing against recombination but rather in favor of a
high degree of conservation in the E7 ORF versus the
other ORFs, resulting from unknown selective pressures.
The E6, E7, and E1P (P, partial) ORFs were compared
within the phylogenetically closest related HPV types,
HPV 3, HPV 10, HPV 28, HPV 29, and HPV 77. The degree
of similarity is indicated in Table 3. The high selective
TABLE 1
Positions of the Major and Minor ORFs
ORF
HPV 75 HPV 76 HPV 77 HPV 80
First
nt
First
ATG
Last
nt
Amino
acids
First
nt
First
ATG
Last
nt
Amino
acids
First
nt
First
ATG
Last
nt
Amino
acids
First
nt
First
ATG
Last
nt
Amino
acids
E6 — 200 613 138 155 200 613 138 6 102 545 148 179 200 622 141
E7 595 613 915 101 595 613 915 101 479 524 793 90 604 622 900 93
E1 767 905 2731 609 860 905 2731 609 797 803 2785 661 803 896 2710 605
E2 2652 2721 4127 469 2646 2721 4154 478 2700 2772 3890 373 2625 2700 4031 444
E4 3238 — 3882 215 3238 — 3909 224 3244 — 3651 136 3082 — 3786 235
L2 4166 4193 5755 521 4194 4221 5783 521 4231 4249 5805 519 4087 4105 5703 533
L1 5759 5771 7297 509 5787 5799 7325 509 5579 5603 7297 565 5685 5718 7238 507
5693 535
5705 531
5789 503
TABLE 2
Percentage Similarity between the Nucleotide Sequences and the Identity between the Amino Acid Sequences
of the Most Closely Related HPV Types
ORF
HPV29/77 HPV75/76 HPV76/49 HPV75/49 HPV15/80
nt aa nt aa nt aa nt aa nt aa
E6 82.8 80.3 89.8 91.2 78.0 80.3 77.5 78.1 87.2 87.9
E7 97.7 97.8 93.7 93.0 83.1 87.0 83.4 84.0 93.5 88.0
E1 88.1 88.8 94.4 96.9 86.3 87.8 85.5 87.8 90.2 93.5
E2 89.3 85.8 91.4 89.1 78.6 74.7 79.8 75.0 88.6 87.2
E4 88.1 83.9 92.8 88.7 81.1 64.5 82.9 68.1 91.0 82.7
L2 84.0 86.9 90.7 96.7 78.2 86.4 77.7 85.6 87.4 93.2
L1 85.3 91.5 88.2 95.1 79.2 90.2 79.6 89.0 86.8 93.7
URR 82.5 93.0 82.7 80.5 94.8
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conservation of the E7 ORF between the other members
of this group is not as obvious as that between HPV 77
and HPV 29, although the E7 ORF of HPV 10 and HPV 28
shares 90% similarity. None of the neighboring E6 and
E1P ORFs reaches the 90% similarity limit.
The cystein doublets typically found in the E6 of other
HPV types, i.e., four Cys-X-X-Cys motifs separated by 29,
36, and 29 amino acids, respectively (Hirsch-Behnam et
al., 1990), are present in HPV 77 and HPV 29, HPV 15, and
HPV 49. Exceptions are HPV 75 and HPV 76 containing
five such motifs separated by 25, 0, 36, and 29 amino
acids, whereas HPV 80 has four motifs separated by 30,
36, and 29 amino acids.
Important conserved regions within the E7 ORF are
the CR1 and CR2 and the metal binding domain (Halpern
and Mu¨nger, 1995). The E7 ORF usually contains two
Cys-X-X-Cys motifs separated by 29 amino acids in the
metal binding domain. HPV 77 and HPV 29, as well as
HPV 80 and HPV 15, conform to this rule, but HPV 75,
HPV 76, and HPV 49 each contain only the second
Cys-X-X-Cys motif, with a Cys-X-X-X-Cys motif 29 amino
acids upstream. HPV 16 E7 mutants or fragments con-
taining only the Cys-X-X-Cys motif at the C-terminal can
still bind zinc (Rawls et al., 1990) and it is this motif which
is essential for the immortalization of human keratino-
cytes (Jewers et al., 1992), as well as for the transactiva-
tion function of E7 (Watanabe et al., 1990; Storey et al.,
1990). The CR2 domain contains the pRb binding and
CKII phosphorylation sites. These motifs present in each
of the HPV types described here are shown in compar-
ison to the motifs found in the high-risk genital type HPV
16 and the low-risk genital type HPV 6 (Table 4). The CR1
regions of HPV 77 and HPV 29 share identical amino
acids with HPV 16 (high risk) in the amino-terminal half of
the motif (HGXXPTX...), whereas the carboxy-terminal
half shares identical amino acids (...KDIXLDL) with HPV 6
(low risk). A deletion of the middle PTLHE in HPV 16 has
been shown to lead to a reduction in transformation
(Banks et al., 1990; Brokaw et al., 1994) as well as in
transactivation (Phelps et al., 1992; Brokaw et al., 1994).
In vitro studies will show whether the E7 ORFs of HPV 29
and HPV 77 are able to transform primary keratinocytes
similar to the E7 ORF of HPV 16 versus the HPV 6 E7 ORF,
which does not transform. A consensus sequence
(IGKXXTIPDIXL) is noted between the CR1 motifs of the
truly cutaneous types, HPV 15/80 and HPV 75/76/49. The
CKII phosphorylation site (DSSDEEDC) in HPV 77 and
HPV 29 again corresponds to that of the mucosal HPV
types, whereas only the central Gln-Gln-Gln is conserved
in HPV 80/HPV15 and HPV 75/HPV76/HPV49. The ab-
sence of the two Ser residues in these HPV types (an
exception is HPV 75 with one Ser residue) indicates that
phosphorylation cannot occur (Barbosa et al., 1990;
Phelps et al., 1991). The core of the Rb binding site
LXCXE is conserved in the new HPV types, although the
first metal binding Cys-X-X-Cys motif, necessary for full
Rb binding (Huang et al., 1993; Patrick et al., 1994), is
absent in HPV 75/HPV 76/HPV 49.
The E1 ORF is the largest ORF in the HPV types
described here, similar to other HPV types. The sizes of
putative proteins of the E2 and E4 ORFs in HPV 77 are
much smaller (387 and 136 aa, respectively) than the
corresponding proteins in HPV 75, HPV 76, and HPV 80
(469, 478, 444 aa and 215, 224, 235 aa, respectively).
These smaller ORFs correspond rather to the sizes found
in HPV 2 (391 and 132 aa) and HPV 57 (383 and 124 aa)
(Hirsch-Behnam et al., 1990). Both these HPV types are
categorized as cutaneous/mucosal types.
The E2 protein of BPV 1 has been studied extensively.
The E2 protein forms dimers which are mediated through
the DNA binding domain. The latter property and the dimer-
ization cannot be separated (McBride and Myers, 1996). A
highly conserved tryptophane at position 360 is called the
TABLE 4
Comparison between Important Functional Motifs
within the E7 ORF
CR1
pRb binding
site CR2 CKII
HPV 16 HGDTPTLHEYMLDL XLXCXE DSSEEEDE
HPV 6 HGRMVTLKDIVLDL GLXCXE DSSEDEVD
HPV 77 HGPKPTVKDIELDL PLLCNEQ DSSDEEDC
HPV 29 HGPKPTVKDIELDL PLLCNEQ DSSDEEDC
HPV 80 IGKEATIPDIELEL DLHCYEE EETEEEPQ
HPV 15 IGKEATIPDIVLEL DLHCYEE EETEEEPR
HPV 75 IGKQATLPDIVLQE DLQCYED QHSEEELI
HPV 76 IGKEATLPDIVLQE DLQCYEN QDTEEELI
HPV 49 IGKEVTIPDIILQE DLQCYEN LEAEEELI
TABLE 3
Percentage Similarity between the E7 ORF and Its Neighboring
ORFs within the Most Closely Related HPV Group, HPV 3, HPV 10,
HPV 28, HPV 29, and HPV 77
HPV ORF
HPV
3 10 77 29
28 E6 83.1 81.1 77.1 74.8
E7 89.3 90.0 80.4 80.4
E1Pa 88.7 83.5 81.4 81.4
28 10 77 29
3 E6 83.1 81.5 77.6 76.9
E7 89.3 85.1 77.8 77.8
E1P 88.4 81.8 80.9 83.4
29 3 28 10
77 E6 82.9 77.6 77.1 76.7
E7 97.8 77.8 80.4 80.4
E1P 89.7 84.0 83.0 82.3
77 3 10 28
29 E6 82.9 76.6 76.1 74.4
E7 97.8 77.8 80.4 80.4
E1P 89.7 82.3 83.0 85.7
a Partial E1 ORF.
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tryptophane bridge and can be cross-linked by UV irradia-
tion (Corina et al., 1993; Prakash et al., 1992). Although its
position varies, this residue is present: W357 in HPV 29,
W356 in HPV 77, W447 in HPV 15, W435 in HPV 80, W461 in
HPV 75, W469 in HPV 76, and W480 in HPV 49. In HPV
29/HPV 77 this single Trp is followed by a tyrosine and in
HPV 80/15 and HPV 75/HPV 76/HPV 49 by a serine. A motif
containing two tryptophane residues (WXW) is conserved in
these HPV types downstream of the WS residues. The X in
WXW is an arginine in HPV 29/HPV 77 and a serine in the
other five HPV types.
The E2 proteins are located within the nucleus (Hub-
bert et al., 1988). Two nuclear localization signals have
been identified in BPV 1 E2 proteins (Skiadoupoulos and
McBride, 1996). The second signal (KRCFKKGAR) lies
within the transactivation domain and mutations or de-
letions cause retention to the cytoplasm of the E2 protein
(Abroi et al., 1996). These important amino acids are
conserved in all the HPV types described here (Table 5).
The E2 protein binds to the E2 recognition sites in the
URR of the genome to either transactivate or repress the
viral functions. The amino acid sequence of the DNA
recognition helix is fairly homologous between different
papillomaviruses (McBride and Myers, 1996). The amino
acids which are in direct contact with the DNA is con-
served in the HPV types described in this study (Table 5).
The E4 ORF is located within the region of the E2 ORF.
A start codon is absent in both the HPV 77 and HPV 29
genomes, as well as HPV 75 and HPV 76. It is present in
HPV 49, HPV 15, and HPV 80. All the viruses mentioned,
harbor an acceptor site in their DNA sequence (HPV
29/HPV 77 GTATCTAG/CA; HPV 15/HPV 80 GTTACTAG/
CT; and HPV 75/HPV 76/HPV 49 GTT(C)ACTAG/CT) for
the splicing from the donor site in the E1 gene into the
E4. The E1 donor site of HPV 77 is identical to that of HPV
29 (MADNS) and those of HPV 75 and HPV 76 are
identical to the site in HPV 49 (MADDK). HPV 80 (MSDEK)
differs from HPV 15 (MSDDK) in one amino acid. The
consensus sequence MXDXK is applicable only for the
truly cutaneous group. Also located in the N-terminus of
the E4 proteins is the conserved sequence LLXLL, which
is important for its association with the cellular keratins
and the formation of keratin structures (Roberts et al.,
1994). The only exceptions are HPV 77 (LLDLC) and HPV
29 (LLDLY). The former is identical to the motif found in
HPV 3, HPV 28, and HPV 19 (Doorbar and Myers, 1996).
Another motif present in the C-terminal is DLXDYW,
present in most cutaneous HPV types. Here again, HPV
15/HPV 80 and HPV 75/HPV 76/HPV 49 harbor this motif,
whereas HPV 29 and HPV 77 do not.
The L1 ORF coding for the outer capsid protein is
highly conserved among all papillomaviruses. The L1
ORFs of HPV 75, HPV 76, and HPV 80 all have only one
start codon, whereas HPV 77 has four ATGs (nt 5603,
5673, 5705, and 5789 within the region overlapping L2).
The ORF starting at nt 5789 would result in a putative
protein of 503 amino acids and, by analogy to the L1
proteins of other HPV types, is the most likely start codon
to be used in HPV 77. HPV 77 is also the only one of
these new HPV types of which the L1 ORF partially
overlaps with the L2 ORF.
The L2 ORF displays more sequence divergence. The
stretch of highly basic amino acids (five to eight nucle-
otides of arginine and lysine) which is conserved at the
carboxy terminal of this protein in many HPV types (Hirt
et al., 1990) is also present in the new HPV types de-
scribed here. The consensus sequence, TTPAVLDDITP,
exclusively present in HPV types associated with muco-
sal lesions (Rho et al., 1994), is present only in the HPV
29 and HPV 77 L2 ORFs.
Additional small ORFs have been described for the
cutaneous/mucosal types HPV2/HPV27/HPV57 (Hirsch-
Behnam et al., 1990), the cutaneous type HPV 41 (Hirt et
al., 1990), as well as the mucosal type HPV 59 (Rho et al.,
1994). Additional ORFs (larger than 80 amino acids) are
also present in the majority of these new HPV types. HPV
75 and HPV 76 each contains an extra ORF within the E1
ORF. One additional ORF is present within the E2/E4
ORFs of HPV 75 and HPV 77 and one within the L2 ORF
of HPV 75. HPV 77 contains three additional ORFs within
its L1 ORF, whereas HPV 75 and HPV 76 each has one
additional ORF within this region of the genome. The
HPV 80 genome does not contain any additional ORFs.
The significance of these smaller ORFs can only be
determined through functional assays.
The upstream regulatory regions (URR) usually do not
share extensive sequence similarities (O’Connor et al.,
1995). The URRs of HPV 75/HPV 76 and HPV 15/HPV 80,
however, show a very high similarity of 93.0 and 94.8%,
respectively. The URR of HPV 77 is 688 nucleotides in
length, whereas the other URRs are significantly shorter,
i.e., HPV 75 with 439 nucleotides, HPV 76 with 420
nucleotides, and HPV 80 with 385 nucleotides. A sum-
mary of the most common sequence elements within the
URR are listed in Table 6. The true E2 binding sites vary
among the HPV types described here. HPV 77 contains
only one such E2 binding site, HPV 76 two, HPV 75 three,
TABLE 5
BR2 Site and the DNA Recognition Helix in the E2
BR2
DNA recognition
helix
BPV 1 KRCFKKGAR GXXNXKCXRXR
HPV 77 KRCWKKRGV GDPNSLKCFRYR
HPV 29 KRCWKKRGV GDPNSLKCFRYR
HPV 80 ANCFKKGPQ GDANKLKCFRFR
HPV 15 ANCFKKGPQ GDANKLKCFRFR
HPV 75 ANCFKKGPI GDPNILKCFRYR
HPV 76 INCFKKGPV GDPNILKCFRYR
HPV 49 AQCFKKGPY GDPNILKCFRYR
GDXNXLKCXRXR
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and HPV 80 four E2 binding sites. The sequence motifs
for the transcription factor binding sites mostly consist of
a consensus sequence which renders a sequence com-
parison very difficult to correlate with its actual functional
activity. Many such sequences are scattered throughout
the URRs of the HPV types described here.
DISCUSSION
Phylogenetic analyses of all HPV types have largely mir-
rored the biological grouping of ‘‘cutaneous’’ and ‘‘genital/
mucosal’’ HPV types. Three of our new HPV types fall strictly
into the cutaneous group, whereas HPV 77 is grouped
within the main branch of ‘‘mucosal’’ HPV types. HPV 75 and
HPV 76 are closely related to HPV 49 originally isolated
from a wart of an immunosuppressed patient (Favre et al.,
1989). Phylogenetically HPV 49 belongs to one major
branch (HPV 5 group) of the viruses historically associated
with epidermodysplasia verruciformis (EV). HPV 75 and
HPV 76 have been isolated from benign warts and their
prevalence in other tumors has not yet been determined.
Most closely related to HPV 80 is HPV 15, which belongs to
the other major branch of the EV-HPV group (HPV 9 group).
HPV 80 was isolated from histologically normal skin from
the outer ear canal, whereas HPV 15 has been identified in
benign lesions as well as squamous cell carcinomas of the
skin (Berkhout et al., 1995; de Villiers et al., 1997). HPV 77 is
most closely related to HPV 29. The latter was isolated from
a common wart (Favre et al., 1989) and the most closely
related HPV types are HPV 3, HPV 10, and HPV 28, all
mainly associated with lesions of cutaneous rather than of
mucosal origin, despite their phylogenetic classification as
mucosal (Chan et al., 1995). The analysis of the DNA se-
quences of the respective ORFs interestingly reveals fea-
tures characteristic for either the cutaneous group or for the
group intermediate to the cutaneous and mucosal.
The E6 and E7 ORFs are responsible for the immortal-
ization capacity of the high-risk mucosal (genital) HPV
types. Very little is known about the intracellular functions of
the different ORFs of the cutaneous types in human kera-
tinocytes. No obvious differences could be detected within
the E6 ORFs of the HPV types described here in compari-
son to other known HPV types. The E7 ORF, however,
harbored several differences, some of which may have
functional consequences. The E7 ORF of HPV 77 shares
several characteristics with the mucosal HPV types. The
CR1 domain of HPV 77 interestingly shares identical amino
acids with HPV 16 in the amino-terminal half of the motif,
whereas the carboxy-terminal half is identical to that of HPV
6, a low-risk mucosal type. The five amino acids PTLHE
located in the center of this motif in the HPV 16 E7 have
been demonstrated to play a crucial role in the transforma-
tion process. HPV 77 was isolated from a benign wart, but
was subsequently demonstrated in 3/32 (9%) dysplastic
warts and in 3/20 (15%) squamous cell carcinomas of skin
(Shamanin et al., 1994b). Its putative role in the immortal-
ization process of human keratinocytes will have to be
demonstrated. The consensus sequence noted in the CR1
of HPV 75, HPV 76, and HPV 80 has been found only in the
truly cutaneous HPV types. These latter HPV types do
contain the core pRb binding site in the CR2 region of their
E7 ORFs, although they do not harbor the CKII phosphory-
lation site. Immortalization of keratinocytes by HPV 16 also
requires the two Cys-X-X-Cys elements within the metal
binding domain of the E7 ORF. The first Cys-X-X-Cys is
necessary for the full binding of pRb, whereas the second
is essential for immortalization of human keratinocytes.
Here again HPV 77 complies with the characteristics
present in HPV 16, whereas HPV 75 and HPV 76 contain
only the second Cys-X-X-Cys element. HPV 80 also has two
of these elements. In vitro analyses of the E7 proteins of
each of the new HPV types need to be performed to deter-
mine whether the deviations in the conserved amino acid
sequences have functional effects.
The extreme difference in similarities among the ORFs
E6 (82.8%), E7 (97.7%), and L1 (85.3%) of HPV 77 and its
closest relative HPV 29 poses the question whether
recombination between HPV types has occurred during
the course of evolution. This possibility cannot be explic-
ity excluded, but present evidence rather argues against
such an event: (a) If a recombinational event inserted an
E7 sequence closely related to the E7 of HPV 29 into HPV
77, one might expect the neighboring E1 sequences to
show a continued high similarity up to a recombinational
breakpoint, but the 300 nucleotides of the E1 ORF next to
the E7 display a distinctly lower similarity between HPV
77 and HPV 29 than the E7 ORFs, with an even distribu-
tion of mismatches. (b) A comparison of the E6 and E7
ORFs and the neighboring 300 nucleotides of the E1 ORF
within the closely related group of HPV 3, HPV 10, HPV
28, HPV 29, and HPV 77 (Table 3) shows no conclusive
pattern indicating recombinational events. In addition,
the E7 ORFs in the case of HPV 10 and HPV 28 also
display a very high degree of conservation when com-
pared to the E6 and E1P ORFs. In addition, the conser-
vation of the E7 ORF may have provided a specific
advantage of survival for this virus type, possibly due to
its preference for specific, not yet defined, target cells.
The definition of a new papillomavirus type has,
during the past, been dependent on the data available
TABLE 6
Nucleotide Positions of the Most Common Sequence Elements
within the URR
Sequence HPV 75 HPV 76 HPV 77 HPV 80
AATAAA 7325 7353 7424 7257
(Polyadenylation signal) 7484 7265
7768 126
ACCG(N4)CGGT 7300 7436 38 7241
(E2 binding site) 7408 77 7336
59 37
65
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at the various points in time. The sequence data of the
majority of the known HPV types have only recently
become available. To date 80 HPV types have been
isolated and their complete genomes characterized. In
addition, another ca. 60–70 putative new types have
been identified through the PCR amplification of par-
tial sequences. The high similarity throughout the ge-
nomes of HPV 75 and HPV 76, with the exception of the
E6 and the L1 ORFs, is notable. Even the URR, which
is characteristically heterogenous between HPV types,
shares a similarity of over 90% between HPV 75/HPV
76 and HPV 15/HPV 80. Such an overall genome sim-
ilarity, along with a relatively high divergence of the
type-specific antigen L1, has to date not been noted
between other closely related HPV types. The se-
quence data presented in this study led to a proposed
modification of the definition of a new HPV type. There
are indications that many HPV types have not yet even
been identified. The isolation and characterization of
the already identified, as well as of the yet unknown,
papillomavirus types may, in future, lead to a complete
reclassification of this virus group. The continuing
detection of putatively new papillomavirus types in a
broad spectrum of tumors being investigated at
present demonstrates the importance of the inclusion
of biological criteria in any future classification.
MATERIALS AND METHODS
Biopsy WV-8346 was taken from a dysplastic wart and
WV-8636b and WV-8495 each from a benign wart in renal
transplant recipients. Biopsy WV-95B was taken from
histologically normal skin of the outer ear canal. Cellular
DNA was extracted by phenol/chloroform/isoamylalco-
hol after Proteinase K–SDS digestion, as previously de-
scribed (Egawa et al., 1993). The partial L1 sequences
were amplified using degenerate forward and backward
primers and the amplified products detected by hybrid-
ization to a degenerate radiolabeled probe (Shamanin et
al., 1994a). The amplified DNA samples which resulted in
a positive hybridization signal (VS40-7 from WV-8346,
CR148 from WV-8636b, VS93-1 from WV-8945, and KB
from WV-95B, respectively) were gel-purified (Geneclean
Kit, BIO 101), cloned in the pBluescript II (KS) phagemid
vector (Stratagene) and sequenced (Shamanin et al.,
1994b; Bergmann et al., 1994). The DNA similarity of each
of these partial L1 sequences was less than 90% to the
closest related known HPV type.
Cellular DNA libraries were constructed from each of
the biopsies. The complete genomes (ca. 8 kb) were
cloned into the EcoRI restriction sites for VS40-7-G (HPV
75), CR148-G (HPV 76), and KB-G (HPV 80), whereas
VS93-1-G (HPV 77) was cloned in two fragments (ca. 3.5
and 4.0 kb) at the BamHI restriction sites in the viral DNA.
The vectors used were Lambda Zap Express (Strat-
agene) for VS40-7-G, CR148-G, and VS93-1-G and l1149
for KB-G and packaged using the Gigapack Gold Pack-
aging Kit (Stratagene). The individual partial L1 cloned
fragments were used as radiolabeled probes to identify
plaques containing the viral DNA. The VS40-7-G and the
larger fragment of VS93-1-G were rescued in the pBK-
CMV plasmid from the Lambda Zap Express (according
to the specifications of the manufacturers) and CR148-G
was subcloned into the vector pUC19. The smaller frag-
ment of VS93-1-G and the KB-G were maintained in the
respective lambda vectors.
The sequencing of HPV 75 (in pBK-CMV) and HPV 76
(in pUC19) was done using the radioactive dideoxy ter-
mination method (Sanger et al., 1977). T7 DNA polymer-
ase (Pharmacia) was used to incorporate 33P-labeled
dATP (Hartmann Analytic). The incorporation of the
dideoxynucleotides into the sequencing product was im-
proved by the use of manganese containing buffer as
described by Tabor and Richardson (1989). Initial se-
quences were obtained using general vector primers
and were extended by primer walking using synthetic
primers.
The large BamHI fragment of HPV 77 (about 4.3 kb, in
pBK-CMV) was sequenced using the same procedure.
The smaller fragment (about 3.7 kb, in Lambda ZAP
Express) was first amplified by the PCR method (Expand
long template PCR system, Boehringer) using primers
derived from pBK-CMV and then sequenced by fluores-
cent dye-labeled terminator cycle sequencing (Perkin–
Elmer, ABI Model 377A).
HPV80 (in l1149) was initially sequenced radioactively,
starting with the L1 partial sequence obtained from the
original general primer amplificate. Primers derived from
the cI gene of l434 did not yield an amplification product
of the full insert but could be used to obtain the vector/
insert sequences. Direct sequencing on the l DNA was
done using 33P-labeled dideoxy terminators and cycle
sequencing (Amersham). Primers derived from the new
sequences were eventually used to amplify about 4 kb of
HPV DNA from the l clone. The sequence of this DNA
was determined by fluorescent sequencing as described
above.
The nucleotide sequence data reported in this paper
have been submitted to the EMBL Nucleotide Sequence
Database and have been assigned the following Acces-
sion numbers: HPV 75—Y15173; HPV 76—Y15174; HPV
77—Y15175; HPV 80—Y15176.
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